Norlase secures €20million venture debt from the European Investment Bank to fuel accelerated growth worldwide

Medical device pioneer, Norlase, has secured €20million venture debt financing from Europe’s leading venture debt provider, EIB. 

The funding provides additional capital to facilitate an aggressive acceleration of sales across new sectors globally, with Norlase targeting a substantially more expansive strategy across new markets and with the potential to generate significant and very high margin revenues.

Norlase is a world class potential category defining technology business that is achieving rapid growth, delivering revolutionary innovations that have been described as equally impactful on the ophthalmic medical treatment sector as the Apple iphone was on the telecommunications sector. 

The Company’s ultra compact, low cost and high-power semi-conductor laser technology is adopted by doctors around the world, transforming the treatment of common eye diseases with a superior, cheaper, more efficient and ultra-portable suite of products. 

Norlase is expecting record breaking revenues this year, following the launch of its fourth most innovative product to date, LYNX, the World’s first laser headset with pattern capability and one of the most groundbreaking innovations in this sector in recent decades. 

Beyond that, similarly groundbreaking innovations are being targeted across substantial adjoining markets, positioning Norlase as the global market leader within laser-based healthcare solutions.

Ioannis Tsakiris of EIB commented;

‘Norlase’s technology is top of its class and a real example of excellence in European innovation.

With the support of Invest EU, the EIB finances projects that advance state-of-the-art medical treatment, and this funding aims to enhance the position of Norlase as a European med-tech champion.’

Norlase CEO, Oliver Hvidt, commented;

 ‘This funding from the EIB allows us to scale our global presence and push even further beyond the limits of existing technology, solidifying Norlase’s role as a leader in the future of eye care. 

We’re just getting started.’